252. Factor SA, Brown D. Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord. 1992;7(2):125-31. doi: 10.1002/mds.870070205. PMID: 1350059.
253. Lonergan E, Britton AM, Luxenberg J, Wyller T (2007) Antipsychotics for delirium. Cochrane Database Syst Rev. https://doi. org/10.1002/14651858.CD005594.pub2
254. Boettger S, Jenewein J, Breitbart W (2015) Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: a comparison of efficacy, safety, and side effects. Palliat Support Care 13:1079–1085
255. Dag Aarsland, MD, PhD; Robert Perry, FrCPath; Jan P. Larsen, MD, PhD; Ian G. McKeith, FRCPysch; John T. O'Brien, MRCPsych; Elaine K. Perry, PhD; David Burn, MD; and Clive G. Ballard, MRCPsych, MD. Neuroleptic Sensitivity in Parkinson's Disease and Parkinsonian Dementias. J Clin Psychiatry 2005;66(5):633-637
256. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzen- schlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sam- paio C (2011) The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 26(Suppl 3):42–80
257. Inzellberg R., Bonuccelli U., Schechtman E. Association between amantadine and onset of dementia in Parkinson disease. Mov Disord.2006; 21(9):1375-9.
258. Hanagasi H.A., Gurvit H., Unsalan P., et al. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo- controlled, multicenter study. Mov Disord. 2011;26(10):1851-8.
259. Frakey L.L., Friedman J.H. Cognitive effects of rasagiline in mild‐to‐moderate stage Parkinson's disease without dementia. J Neuropsychiatry Clin Neurosci. 2017;29:22‐25.
260. Скоромец А.А., Тимофеева А.А., Алиев К.Т. и др. Когнитивные функции при болезни Паркинсона и паркинсонизме, их коррекция пронораном. Эффективная фармакотерапия. 2014; N.17: С. 6-14.
261. Begemann M. J., Brand B.A., Ćurčić-Blake B. et al. Efficacy of non-invasive brain stimulation on cognitive functioning in brain disorders: a meta-analysis. Psychol Med. 2020; 50(15):2465-2486.
262. Biundo R., Weis L., Fiorenzato E. et al. Double‐blind randomized trial of tDCS versus sham in Parkinson patients with mild cognitive impairment receiving cognitive training. Brain Stim. 2015;8:1223‐1225.
263. Nikolin S., Huggins C., Martin D. et al. Safety of repeated sessions of transcranial direct current stimulation: a systematic review. Brain Stim. 2018; 11:278‐288.
264. Petersen R.C., Lopez O.L., Armstrong M.J. Practice guideline update summary: Mild cognitive impairment. Neurology. 2018; 90: 126 – 135.
265. Ferreira J.J., Katzenschlager R., Bloem B. R. et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol. 2013; 20(1):5-15.
266. Green A.R., Oh E., Hilson L. et al. Anticholinergic burden in older adults with mild cognitive impairment. J. Am. Geriatr. Soc. 2016; 64: 313 - e314.
267. Ehrt U., Broich K., Larsen J.P. et al. Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. J Neurol Neurosurg Psychiatry. 2010; 81:160‐165.
268. Song D., Yu D.S.F., Li P.W.C., Lei Y. The effectiveness of physical exercise on cognitive and psychological outcomes in individuals with mild cognitive impairment: A systematic review and meta-analysis. Int J Nurs Stud. 2018; 79: с. 155 – 164.
269. Northey J.M., Cherbuin N., Pumpa K.L. et al. Exercise interventions for cognitive function in adults older than 50: a systematic review with meta-analysis. Br J Sports Med. 2018; 52(3): с. 154 – 160.
270. Murray D. K. The effects of exercise on cognition in Parkinson’s disease: a systematic review. Transl Neurodegener. 2014; 3(1): p. 5.
271. Seppi K., Chaudhuri K.R., Coelho M. et al. Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review. 34(2): 180–198. Mov Disord. 2019;
272. Barha C.K., Davis J.C., Falck R.S. et al. Sex differences in exercise efficacy to improve cognition: A systematic review and meta-analysis of randomized controlled trials in older humans. Front Neuroendocrinol. 2017; 46: с. 71 - 85.
273. Teixeira‐Machado L., Araujo F.M., Cunha F.A. et al. Feldenkrais method‐based exercise improves quality of life in individuals with Parkinson's disease: a controlled, randomized clinical trial. Altern Ther Health Med. 2015;21:8‐14.
274. Chandler M.J., Parks A.C., Marsiske M. et al. Everyday Impact of Cognitive Interventions in Mild Cognitive Impairment: a Systematic Review and Meta-Analysis. Neuropsychol Rev. 2016; 26(3): с. 225 – 251.
275. Hill N.T., Mowszowski L., Naismith S.L., et al. Computerized Cognitive Training in Older Adults With Mild Cognitive Impairment or Dementia: A Systematic Review and Meta-Analysis. Am J Psychiatry.2017; 174(4): с. 329 – 340.
276. Leung I.H., Walton C.C., Hallock H. et al. Cognitive training in Parkinson disease: a systematic review and meta‐analysis. Neurology. 2015; 85:1843‐1851.
277. Cerasa A., Gioia M.C., Salsone M. et al. Neurofunctional correlates of attention rehabilitation in Parkinson's disease: an explorative study. Neurological Sci. 2014;35:1173‐1180.
278. Petrelli A., Kaesberg S., Barbe M.T. et al. Effects of cognitive training in Parkinson's disease: a randomized controlled trial. Parkinsonism Relat Disord .2014;20:1196‐ 1202.
279. Alzahrani H., Venneri A. Cognitive rehabilitation in Parkinson’s disease: a systematic review. Journal of Parkinson’s Disease. 2018; 8(2):233–245.
280. Mamikonyan E., Xie S.X., Melvin E., Weintraub D. Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo-controlled study. Mov. Disord. 2015; 30:912–918.